產(chǎn)品編號(hào) yb-2168R
英文名稱(chēng) Anti-ADAR1抗體
中文名稱(chēng) 雙鏈RNA腺苷酸脫氨基酶抗體（C端）
別    名 136kDa double stranded RNA binding protein; Adar 1; ADAR; Adar1; Adenosine deaminase RNA specific 1; Adenosine deaminase RNA specific; Adenosine deaminase that act on RNA; AV242451; Double stranded RNA specific adenosine deaminase; Double-stranded RNA-specific editase Adar; Drada; Dsh; Dsrad; dsRNA adenosine deaminase; EC 3.5.4.-; G1P1; IFI 4; IFI4; Ifi4 protein; Interferon induced protein 4; Interferon inducible protein 4; K88dsrbp; mZaADAR; p136; Pre-mRNA adenosine deaminase; RNA adenosine deaminase 1; RNA-editing deaminase 1; RNA-editing enzyme 1.
Anti-ADAR1抗體   
說(shuō) 明 書(shū) 0.1ml  0.2ml  
研究領(lǐng)域 細(xì)胞生物  免疫學(xué)  細(xì)胞周期蛋白  
抗體來(lái)源 Rabbit
克隆類(lèi)型 Polyclonal
交叉反應(yīng) Human, Mouse, Rat, 
產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)） 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 135kDa
細(xì)胞定位 細(xì)胞核 細(xì)胞漿 
性    狀 Lyophilized or Liquid
濃    度 1mg/1ml
免 疫 原 KLH conjugated synthetic peptide derived from human DRADA
亞    型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

PubMed PubMed
產(chǎn)品介紹 background:
This gene encodes the enzyme responsible for RNA editing by site-specific deamination of adenosines. This enzyme destabilizes double-stranded RNA through conversion of adenosine to inosine. Mutations in this gene have been associated with dyschromatosis symmetrica hereditaria. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2010]

Function:
Converts multiple adenosines to inosines and creates I/U mismatched base pairs in double-helical RNA substrates without apparent sequence specificity. Has been found to modify more frequently adenosines in AU-rich regions, probably due to the relative ease of melting A/U base pairs as compared to G/C pairs. Functions to modify viral RNA genomes and may be responsible for hypermutation of certain negative-stranded viruses. Edits the messenger RNAs for glutamate receptor (GLUR) subunits by site-selective adenosine deamination. Produces low-level editing at the GLUR-B Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Binds to short interfering RNAs (siRNA) without editing them and suppresses siRNA-mediated RNA interference. Binds to ILF3/NF90 and up-regulates ILF3-mediated gene expression.

Subunit:
Homodimer. Isoform 1 interacts with ILF2/NF45 and ILF3/NF90.

Subcellular Location:
Cytoplasm. Nucleus, nucleolus. Isoform 1: Cytoplasm. Note=Found predominantly in cytoplasm but appears to shuttle between the cytoplasm and nucleus. Isoform 5: Nucleus, nucleolus.

Tissue Specificity:
Ubiquitously expressed, highest levels were found in brain and lung.

Post-translational modifications:
Sumoylation reduces RNA-editing activity.

DISEASE:
Defects in ADAR are a cause of dyschromatosis symmetrical hereditaria (DSH) [MIM:127400]; also known as reticulate acropigmentation of Dohi. DSH is a pigmentary genodermatosis of autosomal dominant inheritance characterized by a mixture of hyperpigmented and hypopigmented macules distributed on the dorsal parts of the hands and feet.

Similarity:
Contains 1 A to I editase domain.
Contains 2 DRADA repeats. 
Contains 3 DRBM (double-stranded RNA-binding) domains.


Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.